Exploring the therapeutic potentials of Bischofia javanica: Evidence of analgesic, antidiarrheal, and hypoglycemic activities

IF 1.7 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2026-02-01 Epub Date: 2026-01-02 DOI:10.1016/j.phytol.2025.104099

Payar Hossain , Md. Hossain Rasel , Md. Jahirul Islam Mamun , Md. Abdul Alim , S.M. Naim Uddin

引用次数: 0

Abstract

Bischofia javanica (Euphorbiaceae) has been used for a long time to manage ulcers, bone fractures, dislocations, inflammation, and tuberculosis. This study evaluated the analgesic, antidiarrheal, and hypoglycemic effects of the methanolic fruit extract (MFBJ) and n-hexane fraction (NHF) of the plant. At 400 mg/kg, both reduced pain in the writhing test (56.74 % and 51.63 %; p < 0.001) and prolonged hot plate response times. MFBJ also showed stronger antidiarrheal (68.65 %) and hypoglycemic (5.92 ± 0.03 mmol/L; p < 0.001) effects. Findings suggest therapeutic potential, warranting further characterisation of bioactive compounds.

查看原文本刊更多论文

探索爪哇花的治疗潜力：镇痛、止泻和降糖活性的证据

长时间以来，大戟科植物被用于治疗溃疡、骨折、脱臼、炎症和肺结核。本研究评估了该植物的甲醇果实提取物（MFBJ）和正己烷部分（NHF）的镇痛、止泻和降糖作用。当剂量为400 mg/kg时，扭体试验疼痛减轻（56.74 %和51.63 %;p <； 0.001），热板反应时间延长。MFBJ还具有较强的止泻（68.65 %）和降糖（5.92 ± 0.03 mmol/L; p <； 0.001）效果。研究结果表明，治疗潜力，保证进一步表征的生物活性化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.